Abivax reports positive Phase 3 results for ulcerative colitis drug

June 1, 2026 4:05 PM

Abivax SA (Euronext Paris: ABVX, NASDAQ: ABVX) announced that its investigational drug obefazimod met the primary ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found